Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 18 | BrightPath Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07777471 | Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia(ACTIVE DEFAULT) | not yet recruiting | N/A | 40 | University of Alabama at BirminghamOTHER |
| 1 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT07778212 | Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL | recruiting | N/A | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07779018 | CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy | recruiting | Phase 2 | 30 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07780565 | Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT02835222 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | active not recruiting | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04007029 | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04404088 | Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04792502 | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | recruiting | Phase 2 | 52 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05110742 | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05197192 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | recruiting | Phase 3 | 202 | German CLL Study GroupOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05579132 | A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) | recruiting | Phase 1 / Phase 2 | 203 | MSD R&D (China) Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies(MORE) | active not recruiting | Phase 2 | 29 | Franziska WachterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05922904 | PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 171 | Kura Oncology, Inc.INDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06066359 | Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma | recruiting | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06297551 | Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) | recruiting | — | 20 | Suhu LiuOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06645093 | Feasibility of Intermittent Fasting During Chemotherapy(FasteStudien) | recruiting | N/A | 40 | University of OsloOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06678659 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer(DAHLIA) | recruiting | Phase 1 / Phase 2 | 170 | Recursion Pharmaceuticals Inc.INDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06756308 | A Study of Enasidenib in People With T-Cell Lymphoma | active not recruiting | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | recruiting | Phase 3 | 1,300 | Kura Oncology, Inc.INDUSTRY | 16 | Aug 20, 2026 | clinicaltrials |
| NCT07021989 | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 38 | Michael Spinner, MDOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07137481 | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies | not yet recruiting | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07275216 | Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | recruiting | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07514936 | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | recruiting | Phase 3 | 120 | Chinese PLA General HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07649681 | Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention(GustaborRCT) | recruiting | N/A | 198 | Wuerzburg University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775508 | In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 18 | Chinese PLA General HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777120 | Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | active not recruiting | — | 300 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777406 | Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma(MAIELLA) | recruiting | — | 60 | Università degli Studi 'G. d'Annunzio' Chieti e PescaraOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT02390869 | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients(FIL_RENOIR12) | active not recruiting | Phase 3 | 128 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | active not recruiting | Phase 3 | 280 | Children's Oncology GroupNETWORK | 6 | Aug 19, 2026 | clinicaltrials |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 66 | AbbVieINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients(CASSIOPEIA) | active not recruiting | Phase 2 | 121 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 19, 2026 | clinicaltrials |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | recruiting | Phase 3 | 288 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | recruiting | Phase 3 | 1,450 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT04898790 | Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant(PROACTIVE) | recruiting | N/A | 114 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05011422 | Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies | recruiting | Phase 1 | 50 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05082519 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL(IDEAL2) | recruiting | Phase 2 | 240 | Etan OrgelOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05173961 | A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 21, 2026source: clinicaltrials